SageView Advisory Group LLC Takes Position in Insulet Co. (NASDAQ:PODD)

SageView Advisory Group LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,088 shares of the medical instruments supplier’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Capital Research Global Investors raised its holdings in shares of Insulet by 19.7% in the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after purchasing an additional 1,556,455 shares in the last quarter. Baillie Gifford & Co. purchased a new position in shares of Insulet in the 4th quarter valued at $263,144,000. Norges Bank purchased a new position in shares of Insulet in the 4th quarter valued at $227,655,000. Goldman Sachs Group Inc. grew its position in shares of Insulet by 56.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock valued at $190,623,000 after buying an additional 316,649 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its position in shares of Insulet by 10.7% in the 4th quarter. Westfield Capital Management Co. LP now owns 705,429 shares of the medical instruments supplier’s stock valued at $153,064,000 after buying an additional 68,168 shares during the last quarter.

Insulet Stock Up 1.5 %

PODD stock opened at $199.31 on Friday. Insulet Co. has a one year low of $125.82 and a one year high of $298.95. The stock has a market capitalization of $13.96 billion, a PE ratio of 60.40, a price-to-earnings-growth ratio of 3.54 and a beta of 1.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. The company has a fifty day moving average of $179.00 and a 200-day moving average of $185.96.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. During the same quarter last year, the business earned $0.23 earnings per share. The business’s revenue for the quarter was up 23.3% compared to the same quarter last year. As a group, analysts expect that Insulet Co. will post 3.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PODD shares. Raymond James dropped their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Canaccord Genuity Group increased their target price on shares of Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group increased their target price on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Redburn Atlantic began coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective on the stock. Finally, Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research report on Tuesday, May 7th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average target price of $239.18.

Insider Activity at Insulet

In related news, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of Insulet stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the transaction, the director now owns 42,586 shares in the company, valued at $7,703,807.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark N. Field sold 1,500 shares of Insulet stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock worth $2,636,286 over the last 90 days. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.